Table 1.

Talazoparib implants decrease tumor size and extend survival in BRCA1-deficient mice

	Initial Tumor Volume (mm3)	Final Tumor Volume (mm3)	# of mice/group	Lifespan after treatment (days)
0 µg control implant (1mm)	66.7 ± 27.5	504 ± 67.4a	5	11.8 ± 1.9
25 µg Talazoparib implant	130.1 ± 42	65.4 ± 14.1b	8	29 ± 3g
0 µg control implant (2mm)	72.1 ± 24.9	484.3 ± 68.8c	7	11.9 ± 1.4
50 µg Talazoparib implant	44.4 ± 5.2	14.9 ± 5.7c,d,e	7	44.1 ± 1.8h
50 µg Talazoparib gavage	55.4 ± 16.2	537.1 ± 244.2f	6	39.8 ± 6.4h

Values are mean ± SEM.

a, P = 0.002 0 µg control implant (1mm) final volume vs. initial volume b, P = 0.002 25 µg Talazoparib implant final volume vs. 1mm control final volume c, P < 0.001 50 µg Talazoparib implant final volume vs. 2mm control final volume d, P < 0.05 50 µg Talazoparib implant final volume vs. 50 µg Talazoparib implant initial volume e, P < 0.001 50 µg Talazoparib implant final volume vs. 50 µg Talazoparib gavage final volume f, P = 0.026 50 µg Talazoparib gavage final volume vs. initial volume g, P < 0.001 25 µg Talazoparib implant vs. 0 µg control implant (1mm) h, P < 0.001 50 µg Talazoparib implant and 50 µg Talazoparib gavage vs. 0 µg control implant (2mm)